

07/25/2012

Curriculum Vitae
Awewura Kwara, MB.ChB., MPH&TM

PERSONAL INFORMATION

Home address: 15 Desmarais Street, Cumberland, RI 02864
Business address: The Miriam Hospital
Department of Medicine
164 Summit Avenue, RISE Bldg.
Providence, RI 02906
Telephone Number (401) 793-2463
Fax Number: (401) 793-4704
Electronic Mail Address akwara@lifespan.org

EDUCATION

Medical School	1986-1992	MB.ChB., University of Ghana Medical School, Accra, Ghana.
Other Degrees	2000-2001	MPH&TM, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA. Tropical Medicine.

POSTGRADUATE TRAINING

Residency	1996-1999	Intern and Resident, Internal Medicine, Cook County Hospital, Chicago, IL.
Fellowship	1999-2002	Infectious Diseases, Tulane University School of Medicine, New Orleans, LA.

POSTGRADUATE HONORS AND AWARDS

2001 Wetmore Foundation Fellowship for Tuberculosis/HIV

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

Diplomate, American Board on Internal Medicine, 1999 (Re-certified 2009)
Diplomate, American Board of Infectious Diseases, 2001 (Re-certified 2011)

ACADEMIC APPOINTMENTS

2001-2002	Clinical Instructor in Medicine, Tulane University School of medicine
2002-2003	Clinical Instructor, Warren Alpert Medical School of Brown University
2003-2012	Assistant Professor of Medicine, Warren Alpert Medical School of Brown University

2003-Present Associate Professor of Medicine, Warren Alpert Medical School of Brown University

HOSPITAL APPOINTMENTS

2002-present Active Staff Physician, The Miriam Hospital
2002-present Active Staff Physician, Rhode Island Hospital
2003-2006 Staff Physician, Landmark Hospital
2009 -present Active Consulting Physician, Women and Infants Hospital

OTHER APPOINTMENTS

1994-1995 Medical Officer, Korle-Bu Teaching Hospital, Accra, Ghana
1995-1996 Medical Officer, Medical Research Council Laboratories, Fajara, Gambia
2001-2002 Member, Infection Control Committee, Charity Hospital, New Orleans, LA
2005-2006 Member, Opportunistic Infections Subcommittee, Adult Clinical Trials Group (ACTG)
2006-2007 Member, Tuberculosis Working Group, ACTG
2007 Grant Reviewer, Canadian Institute of Health Research
2008 Ad hoc Grant Reviewer, Center for Scientific Review, Fogarty Center NIH
2009 - Member, Inter-CFAR HIV/TB Working Group
2010 Invited Abstract Reviewer. AIDS 2010 Conference
2011 Co-Director, Lifespan/Brown/Tufts CFAR International Program
2011 Member, Tuberculosis Transformative Science Group, ACTG
2011 Editorial Board Member, Journal of Pharmacogenomics and pharmacoproteomics

MEMBERSHIP IN SOCIETIES

2001- American college of Physicians
2001-2009 American Society of Tropical Medicine and Hygiene
2002- Infectious Diseases Society of America
2003- American Society of Microbiology

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. **Kwara A**, Adegbola RA, Corrah PT, Weber M, Achtman M, Morelli G, Caugant DA, Greenwood BM. Meningitis caused by a serogroup W-135 clone of the ET-37 complex of *Neisseria meningitidis* in West Africa. *Tropical Medicine and International Health* 1998; 3:742-746.
2. Weber MW, Milligan P, Giadom B, Pate MA, **Kwara A**, Sadiq AD, Chanayireh M, Whittle H, Greenwood BM, Mulholland K. Respiratory illness after severe *Respiratory syncytial virus* infection in infancy in the Gambia. *J Pediatr* 1999;135:683-8.

3. **Kwara A**, Schiro R, Cowan LS, Hyslop NE, Wiser MF, Roahen Harrison S, Kissinger P, Diem L, Crawford JT. Evaluation of the epidemiologic utility of secondary typing methods for differentiation of *Mycobacterium tuberculosis* isolates. *J Clin Microbiol* 2003;41:2683-2685.
4. **Kwara A**, Carter EJ, Rich JD, Flanigan TP. Development of opportunistic infections after diagnosis of active tuberculosis in HIV-infected patients. *AIDS Patient Care and STDS* 2004;18:341-347.
5. **Kwara A**, Flanigan TP, EJ Carter. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. *Int J Tuberc Lung Dis* 2005;9:248-257.
6. **Kwara A**, Roahen Harrison S, Prystowsky E, Kissinger P, Mathison J, Adams R, Hyslop NE. Manifestations and outcome of extrapulmonary tuberculosis: impact of human immunodeficiency virus coinfection. *Int J Tuberc Lung Dis* 2005;9:485-493.
7. **Kwara A**, DeLong A, Rezk N, Hogan J, Burtwell H, Chapman S, Moreira CC, Kurpewski J, Ingersoll J, Caliendo AM, Kashuba A, Cu-Uvin S. Antiretroviral Drug Concentrations and Virologic Rebound in the Genital Tract of HIV-Infected Women on Chronic HAART. *Clin Infect Dis* 2008;46:719-725.
8. **Kwara A**, Herold JS, Machan JT, Carter EJ. Factors Associated with Failure to Complete Isoniazid Treatment for Latent Tuberculosis Infection in Rhode Island. *Chest* 2008;133:862-868.
9. **Kwara A**, Lartey M, Sagoe KW, Xexemeku F, Kenu E, Oliver-Commey J, Boima V, Sagoe A, Boamah I, Greenblatt DJ, Court MH. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. *J Clin Pharmacol* 2008;48:1032-1040.
10. Nijhawan AE, Zachary AC, **Kwara A**, Venna N. Status epilepticus resulting from severe efavirenz toxicity in an HIV-infected patient. *AIDS Read* 2008;18:386-388.
11. **Kwara A**, Lartey M, Sagoe KW, Rezk N, Court MH. CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or *17) Polymorphisms are Independent Predictors of Efavirenz Plasma concentrations in HIV-infected Patients. *Br J Clin Pharmacol* 2009; 67:427-436.
12. **Kwara A**, Lartey M, Boamah I, Rezk N, Oliver-Commey J, Kenu E, Kahusba ADM, Court MH. Pharmacokinetics of NRTIs in TB/HIV co-infected patients: The *UGT2B7*1c* haplotype tagSNP c.735A>G is associated with higher zidovudine glucuronidation. *J Clin Pharmacol* 2009;49:1079-1090.
13. **Kwara A**, Lartey M, Sagoe WC, Kenu E, Court MH. *CYP2B6*, *CYP2A6* and *UGT2B7* genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. *AIDS* 2009;23:2101-6.
14. **Kwara A**, Ramachandran G, Swaminathan S. Dose adjustment of the nonnucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. *Expert Opin Drug Metab Toxicol* 2010;6:55-68.

15. Forson A, Kudzawu S, **Kwara A**, Flanigan TP. Pattern of *Mycobacterium tuberculosis* Drug Resistance among Chronic Pulmonary Tuberculosis Patients at a Tertiary Hospital in Ghana. *Ghana Med J*, 2010;44:42-46.
16. Howley IW, Lartey M, Machan JT, Obo-Akwa A, Flanigan TP, Talbot EA, **Kwara A**. Highly active antiretroviral therapy and employment status in Accra, Ghana. *Ghana Med J* 2010;44:144-149.
17. **Kwara A**, Shah D, Renner LA. Reasons for and outcome of hospital admissions in HIV-infected children at the Korle Bu Teaching Hospital Accra, Ghana. *West Afri J Med* 2010;29:379-83.
18. **Kwara A**, Lartey M, Sagoe KW, Court MH. Paradoxically Elevated Efavirenz Concentrations in HIV/TB Co-infected Patients with CYP2B6 516TT Genotype on Rifampin-containing Antituberculous Therapy (Research Letter). *AIDS* 2011;25:388-390.
19. Lartey M, Sagoe K, Kenu E, Oliver-Commey J, Bioma V, Makafui S, Mingle JAA, Machan J, **Kwara A**. Plasma HIV RNA Dynamics in Response to Efavirenz-based HAART in HIV/TB Co-infected compared to HIV-Mono-infected Patients. *Clin Infect Dis* 2011;52:547-550.
20. Vanhomwegen J, **Kwara A**, Martin M, Gillani F, Muntungi P, Crellin J, Obaro S, Hart C, Carter EJ, Rastogi N. Impact of immigration on the molecular epidemiology of tuberculosis in Rhode Island *J Clin Microbiol* 2011;49:834-44.
21. **Kwara A**, Tashima K, Poethke P, Kurpewski J, Kashuba ADM, Court M. Modest but variable effects of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African American and Caucasian Volunteers. *Antimicrob Agents Chemother* 2011;55:3527-3533.
22. Burton NT, Forson A, Lurie MN, Kudzawu S, Kwarteng E, **Kwara A**. Factors associated with mortality among patients with tuberculosis attending a Teaching Hospital Clinic in Accra, Ghana. *Trans R Soc Trop Med Hyg* 2011;105:3527-33.
23. Temple B, **Kwara A**, Sunesara I, Mena L, Dobbs T, Henderson H, Holcomb M, Webb R. Factors associated with recently transmitted *Mycobacterium tuberculosis* strain MS0006 in Hinds County, Mississippi. *South Med J*. 2011;104:819-826.
24. Haas DW, Kuritzkes DR, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay J, Phillips E, Ribaud HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM, Haubrich R, Kim P, Dehlinger M, Abebe R, Telenti A; Workshop Pharmacogenomics-A Path Towards Personalized HIV Care. Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. *HIV Clin Trials*. 2011;12:277-85.
25. Carten M, Kiser J, **Kwara A**, MaWhinney S, Cu-Uvin S. Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B®), and Efavirenz. *Infect Dis Obst Gyne* vol. 2012, Article ID 137192, 4 pages, 2012. doi:10.1155/2012/137192.

OTHER PEER-REVIEWED PUBLICATIONS

1. **Kwara A**, Feldman S, DeJace PM, Hyslop Jr. NE. An AIDS patient with buttock and thigh swelling. *Infect Med* 2001;18:84-88.
2. **Kwara A**, Pappas PG, Hasbun R, Beilke MA. A lawyer from Honduras with fever and hypotension. *Infect Med* 2001;18:453-4.

3. Ramgoolam A, **Kwara A**, Silio M. A neonate with meningitis. *Infect Med* 2003;20:330-332.
4. Renner L, Ghebremichael M, Goka P, Lartey M, **Kwara A**, Paintsil E. Predictors of the trends in absolute and percentage CD4+ T-lymphocyte in HIV-infected children in Ghana. *Int J Infect Dis* 2011;6:7-15.
5. Kwara A (2012). Towards Individualized HIV Therapy: Pharmacogenetic-guided Clinical Trials are Needed Now. *J Pharmacogenom Pharmacoproteomics* 3:e116.doi:[10.4172/2153645.1000e116](https://doi.org/10.4172/2153645.1000e116)

PUBLICATIONS SUBMITTED OR IN PREPARATION

1. **Kwara A**, Yang H, Lartey M, Sagoe KW, Kenu E, Court MH. Identification of HIV-infected Ghanaian Patients with Low or High Efavirenz Plasma Concentrations. (in preparation).
2. **Kwara A**, Mahjoub B, Cao L, Poethke P, Kurpewski mJ, Tashima KT, Court MH, Peloquin C. Rifampin Pharmacokinetics and Impact of Rifampin Concentrations on Efavirenz Clearance in Healthy Volunteers (in preparation).

ABSTRACT

1. **Kwara A**, Roahen Harrison S, Prystowsky E, Kissinger P, Mathison J, Hyslop NE. Extrapulmonary tuberculosis: A 9-year review of experience in metropolitan New Orleans. Poster presented at Infectious Disease Society of America (IDSA) meeting, Chicago, October 2002. [abstract 669]
2. **Kwara A**, Schiro R, Cowan LS, Hyslop NE, Wisner MF, Roahen Harrison S, Kissinger P, Diem L, Crawford JT. Evaluation of the epidemiologic utility of secondary typing methods for differentiation of *Mycobacterium tuberculosis* isolates. Poster presented at American Thoracic Society (ATS) International Meeting, Seattle, May 2003. [abstract page A609]
3. Roahen Harrison S, **Kwara A**, Schiro R, Wisner MF, Kissinger P, Ratard R, Degraw C, Fernandez M, Jones C, Hyslop NE. Epidemiological risk factors associated with *Mycobacterium tuberculosis* clusters in metropolitan New Orleans. Oral presentation at the American Thoracic Society (ATS) International Meeting, Seattle, May 2003. [abstract page A433]
4. **Kwara A**, Martin M, Gillani F, Mutungi P, Obaro S, Machan J, Crellin J, Gosciminski M, Carter EJ. Missed Opportunities for Tuberculosis Elimination: Lessons from Rhode Island. Poster presented at American Thoracic Society (ATS) International Meeting, Seattle, May 2007. [abstract page A392].
5. Herold J, Machan J, Carter EJ, **Kwara A**. Factors Associated with Latent TB Treatment Outcome in Rhode Island (RI). Poster presented at American Thoracic Society (ATS) International Meeting, San Francisco, May 2007. [abstract page A465]
6. **Kwara A**, DeLong A, Rezk N, Hogan J, Burtwell H, Chapman S, Moreira CC, Kurpewski J, Ingersoll J, Caliendo AM, Kashuba A, Cu-Uvin S. Antiretroviral Drug

Concentrations in the Genital Tract of HIV-Infected Women. Infectious Disease Society of Obstetrics and Gynecology 34th Annual Scientific Meeting, August 9 to 11, 2007, Boston, MA. (Oral Presentation).

7. **Kwara A**, Lartey M, Sagoe K, Oliver-Commey J, Kenu E, Xexemeku F, Boimah V, Sagoe A, Flanigan T, Greenblatt DJ, Court MH. Frequency of Functional *CYP2B6* Variants in Ghanaian TB/HIV Co-infected Patients: Implications for Efavirenz-based Antiretroviral Therapy. First College of Health Sciences Annual Scientific Conference, Accra, Ghana, September 26 - 28, 2007 (Oral Presentation).
8. Lartey M, Sagoe K, Oliver-Commey J, Kenu E, Xexemeku F, Boimah V, Sagoe A, Flanigan T, **Kwara A**. Clinical and Immunological Outcome of Efavirenz-based Therapy in TB/HIV Co-infected Patients at Korle-Bu Teaching Hospital. First College of Health Sciences Annual Scientific Conference, Accra, Ghana, September 26 - 28, 2007. (Oral Presentation).
9. Howley IW, Lartey M, Machan JT, Obo-Akwa A, Flanigan TP, Talbot E, **Kwara A**. The Effect of Highly Active Antiretroviral Therapy on Employment, Accra, Ghana. Poster presented at Infectious Diseases Society of America (IDSA) Annual Meeting, Washington DC, September 2008. [abstract # 2977].
10. **Kwara A**, Lartey M, Boamah I, Rzek N, Oliver-Commey J, Kenu E, Kashuba A, Court M. Variability in the pharmacokinetics of NRTI in TB/HIV Ghanaian patients. Poster presented at 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009), Montreal Canada, February 8-11, 2009. [abstract #699].
11. Carten ML, Kisser J, **Kwara A**, Ma Whinney S, Cu-Uvin S. Pharmacokinetic (PK) interactions between the hormonal emergency contraception plan B® (levonorgestrel) and efavirenz (EFV). Poster presented at 16th Conference on Retroviruses and Opportunistic Infections (CROI 2010), San Francisco, February 16-19, 2010. [abstract # U-115].
12. **Kwara A**, Tashima K, Poethke P, Kurpewski J, Kashuba ADM, Court M. Modest but variable effects of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African American and Caucasian Volunteers. Poster presented at 39th ACCP Annual Meeting, Baltimore, September 12-14, 2010 [abstract #66].
13. Temple B, **Kwara A**, Sunesara I, Mena L, Webb R. The emergence of the MS0006 TB Strain and its Effects on the Homeless and HIV-infected Population of County X in Mississippi. Poster presented at 48th Infectious Diseases Society of America (IDSA) Annual Meeting, Vancouver, Canada, October 21-24, 2010. [abstract # 1295].
14. Wilhelm A, Paci G, Lartey M, **Kwara A**. Treatment default is low among patients initiating HAART at the Korle-Bu Teaching Hospital Clinic in Accra, Ghana. Poster presented at 59th American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting, Atlanta, Georgia, November 3-7, 2010. [abstract # 674].
15. Kwara A, Yang H, Lartey M, Sagoe K, Court MH. Identification of HIV-infected Ghanaian patients with low and high efavirenz plasma mid-dose concentrations. Poster presented at 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy. July 17 - 20 2011 [abstract # MOPE 198].

16. Temple B, Sunesara I, **Kwara A**, Dobbs T, Holcomb M, Webb R. Transmission of HIV and non-HIV TB cases in Mississippi: Intensified Efforts are needed among African Americans and HIV-infected sub-populations. Poster presented at 49th Infectious Diseases Society of America (IDSA) Annual Meeting, Boston, Massachusetts, October 20-23, 2011. [abstract # 995].

INVITED PRESENTATIONS

1. New Orleans Citywide Infectious Diseases Meeting, New Orleans, Louisiana, March 8, 2002. "Extrapulmonary tuberculosis: 9-Years experience in metropolitan New Orleans."
2. ACTG Scientific Meeting, New Orleans, Louisiana, April 4, 2002. "Molecular epidemiology of tuberculosis transmission in Louisiana Public Health Region 1, 1999-2001."
3. Grand Rounds, Landmark Medical Center, Woonsocket, Rhode Island, December 16, 2002. "Natural history of human immunodeficiency virus (HIV) infection: implications for early intervention."
4. Brown University AIDS Clinical Taskforce Meeting, Providence, Rhode Island, January 9, 2003. "Human immunodeficiency virus (HIV) and tuberculosis coinfection."
5. Family Practice Grand Rounds, Memorial Hospital, Pawtucket, Rhode Island, February 6 2003. "Targeted tuberculin testing and treatment of latent TB infection"
6. Infectious Diseases Conference, Rhode Island Hospital, September 15, 2004. "Highly active antiretroviral therapy (HAART) in patients with tuberculosis."
7. Department of Medicine, University of Ghana Medical School, Accra, Ghana. September, 24 2004. "Highly active antiretroviral therapy (HAART) in patients with tuberculosis."
8. Family Practice Grand Rounds, Memorial Hospital, Pawtucket, Rhode Island, January 13 2005. "Targeted tuberculin testing and treatment of latent TB infection"
9. Infectious Diseases Lecture Series, UMass Memorial Medical Center, Worcester, MA. May 6, 2005. "Management of TB and HIV coinfection".
10. Family Resources Community Action, Woonsocket. July 19, 2005. "Infection control for Health Care Personnel".
11. Infectious Diseases Lecture Series, Miriam Hospital, Providence, Rhode Island. September 21, 2006. "Rifampin and Antiretroviral drug Interactions: Implication for Concurrent Therapy".
12. Research Seminar, Medical Research Council Laboratories, Fajara, Gambia, November 20, 2006. "Rifampin and Antiretroviral drug Interactions: Implication for Concurrent Therapy".

13. Lifespan/Brown/Tufts CFAR seminar. March 30, 2007. "Response to Efavirenz-based HAART in TB/HIV Co-infected Patients receiving Rifampin-containing TB treatment in Ghana".
14. Scholarly Concentration on Global Health, Brown University Providence, April 3, 2007. "Staying Healthy While Traveling Abroad".
15. CODAC Behavioral Healthcare of Cranston, RI, May 30, 2007. "Targeted Tuberculin Testing and Treatment of Latent TB Infection".
16. Primary Care Provider Course on HIV Medicine, Miriam Hospital, Providence, July 16-18, 2007. "HIV and TB".
17. Update on HIV/TB Co-infection: Management and Diagnostics. Accra & Kumasi, Ghana, September 19 & 21, 2007. "Treatment of tuberculosis and HIV coinfection".
18. Update on HIV/TB Co-infection: Management and Diagnostics. Accra & Kumasi, Ghana, September 19 & 21, 2007. "Management of multi-drug resistant (MDR) tuberculosis".
19. Lifespan/Brown/Tufts CFAR seminar. Miriam Hospital, March 14, 2008. "Pharmacokinetics and Safety of Efavirenz in the Presence of Rifampin in TB/HIV Co-infected Persons: Pharmacogenetic effect of CYP2B6 variation".
20. Infectious Diseases Conference, Miriam Hospital, Providence, RI, March 19, 2008. "The Pharmacogenetics of Efavirenz Therapy".
21. Unite for Sight Fifth Annual International Health Conference, Yale University, New Haven, CT. April 12, 2008. "Tuberculosis and HIV research at the Korle-Bu Teaching Hospital".
22. CODAC Behavioral Healthcare of Cranston, RI, April 30, 2008. "Targeted Tuberculin Testing and Treatment of Latent TB Infection".
23. SNMA Region VII Annual Conference, December 6, 2008. "The HIV/TB Co-Epidemic: Is the Global response Adequate?"
24. TB: Here and Now: Annual New England Clinicians Conference, Newport, RI, May 1, 2010. "Management of HIV/TB Coinfection".
25. Fourth Annual New England TB Symposium, Broad Institute, Boston, MA, July 16, 2010. Understanding the drug-drug interactions between the NNRTIs and rifampin-containing tuberculosis therapy".
26. Program in Pharmacology and Experimental therapeutics and Program in Cellular and Molecular Physiology Joint Program Seminar, Boston, MA, November 16, 2010. "Drug-drug interactions between efavirenz and rifampin: understanding inter-individual variability".
27. Immunology Conference, Miriam Hospital, Providence, Rhode Island. February 23, 2011. "Management of HIV in TB co-infected Patients".
28. Infectious Diseases Lecture Series, Miriam Hospital, Providence, Rhode Island. February 24, 2011. "Drug-drug interactions between the NNRTIs and rifampin-containing TB therapy".

29. Sub-Saharan Africa CFAR Conference, Serena Hotel, Kampala, Uganda. May 27, 2011. Panel presentation. "Challenges to controlling HIV-associated TB in sub-Saharan Africa".
30. Ghana College of Physicians and Surgeons/West African College of Physicians: Update in Infectious Diseases, Accra, Ghana. June 28, 2011. "Update on the management of HIV/TB coinfection"
31. Ghana College of Physicians and Surgeons/West African College of Physicians: Update in Infectious Diseases, Accra, Ghana. June 28, 2011. "Update on the management of MDR/XDR TB"
32. Ghana College of Physicians and Surgeons/West African College of Physicians: Update in Infectious Diseases, Accra, Ghana. June 29, 2011. "Research proposal writing"
33. University of Ghana College of Health Sciences Faculty Development Workshop, Accra, Ghana. September 20, 2011. "Overview of developmental grants under USAID/HED-funded project and other opportunities"

FUNDED RESEARCH GRANTS

Current funded projects:

NIH/NICHD	7/15/12-4/31/17	4.5 cal. months
1 R01HD071779-01A1	\$603,058/yr	

Title: Pharmacokinetics of anti-tuberculosis and antiretroviral drugs in children
 The goal of this grant is develop a long-term program to study the pharmacokinetics and pharmacogenetics of HIV therapy in children at the Komfo Anokye Teaching Hospital, Kumasi, Ghana.

Role: Principal Investigator

NIH/NAID (PI)	6/1/11-8/31/12	3.24 cal. months
1 R56 AI091448	\$487,804	

Title: Pharmacogenetics and Drug to Drug Interactions during HIV/TB Therapy
 The goal of this grant is to to develop and validate an *in vitro* model for studying drug-drug and drug-gene interactions between TB and HIV drugs.

Role: Principal Investigator

USAID (Flanigan, PI)	7/1/11-6/30/13	1.2 cal. months
Award # AEG-A-00-05-00007		\$1,100,000

University of Ghana/Brown University Academic Partnership to Address HIV/AIDS in Ghana. The goal of this grant is to build capacity of the University of Ghana to conduct research, train and provide community service that contributes to enhanced response to the challenges of HIV/AIDS in Ghana.

Role: Co-Principal Investigator

European and Development Countries Clinical Trials Partnership (EDCTP)
 Professor C.S. Mgone (PI)
 7/7/2008 - 7/6/2013 3,000,000 Euros

Title: Capacity building to prepare West African sites for clinical trials on HIV, TB and malaria. The goal of this grant is to set up nodes of excellence in HIV, TB and malaria research in West Africa.

Role: Co-Investigator (no support), Korle-Bu Teaching Hospital Site, Accra, Ghana.

Past funded projects:

Rhode Island Foundation 12/02-11/03

Grant # 20030199 \$10,000

Title: Molecular Epidemiology of tuberculosis in Rhode Island

The goal of this project is to determine the contributing factors for tuberculosis in Rhode Island as well as the profiles of foreign-born patients in relation to US-born patients that may have implication for control strategies.

Role: Principal Investigator

NIH/NIAID (Carpenter) 2/1/04-11/30/05 10% Effort Only

5-P30 AI42853-07 \$40,000 No Salary Support

Lifespan/Tufts/Brown Center for AIDS Research

Developmental Award

Title: Pharmacokinetics and Virologic Response to Efavirenz-based Antiretroviral Therapy in HIV/TB co-infected Patients Receiving Rifampin-based TB Treatment in sub-Saharan Africa.

Role: Principal Investigator

ACRiA (Lartey, PI) 01/06-12/07 2.5% Effort Only

Doris Duke Foundation \$63,805

AIDS Care Research in Africa Award

Title: Comparison of Responses to Antiretroviral Therapy in HIV-infected Adults with and without Tuberculosis coinfection: Is Outcomes different?

The goal of this study is to compare the efficacy and tolerability of a once daily antiretroviral regimen consisting of lamivudine, didanosine and efavirenz in HIV/TB co-infected and HIV mono-infected patients in Ghana.

Role: Co-Investigator

University of Colorado/BMS 12/8/06-12/7/07 5% Effort

Subcontract \$26,164

Title: A pilot study of the pharmacokinetic interactions between the hormonal emergency contraceptive agent, plan B, and efavirenz

Role: Principal Investigator

USAID Higher Education for Development

Dr Edward Wing (PI)

11/1/09 - 3/31/2010 \$50,000 planning grant

Title: Brown University/University of Ghana College of Health Sciences Higher Education Initiative for HIV/AIDS. The planning grant is to enable the partner universities develop and submit a long-term strategic plan for HIV/AIDS initiative.

Role: Co-Investigator

NIH/NAID (PI)
1K23AI071760-01

8/1/06-6/30/11
\$634,770

50% Effort

Mentored Career Developmental Award

Title: Concurrent HAART and Tuberculosis Treatment: Drug to Drug Interactions
The goal of this grant is to support the training of Dr Awewura Kwara in clinical research related to pharmacokinetics of HIV and TB therapies through a Mentored Patient-Oriented Research Career Developmental Award (K23).

Role: Principal Investigator

UNIVERSITY TEACHING ROLES

Preceptor/mentor for summer research projects. Scholarly Concentration in Global Health. One -two students per year. 2007 - present.

Lecturer, "Helmithises" Introduction to Tropical Medicine. March 20, 2007

Lecturer, "Helmithises" Introduction to Tropical Medicine. January 28, 2009

Lecturer, "HIV and Tuberculosis Research at Korle-Bu Teaching Hospital, Ghana"
Global Health and Medicine Lectures Series. April 9 2008

Lecturer, "HIV and Tuberculosis Research at Korle-Bu Teaching Hospital, Ghana"
Global Health and Medicine Lectures Series. 1/14/2009

Lecturer, "Staying Healthy While Traveling Abroad". Scholarly Concentration on Global Health, Brown University Providence, April 29, 2009.

Lecturer, "Tuberculosis" PHP 1070. Burden of Diseases in Developing Countries.
November 9, 2009.

Lecturer, "Tuberculosis" PHP 1070. Burden of Diseases in Developing Countries.
November 3, 2010

Lecturer, "Tuberculosis" PHP 1070. Burden of Diseases in Developing Countries.
October 31, 2011

HOSPITAL TEACHING ROLES

Preceptor for Infectious Diseases Fellows, Longitudinal Infectious Diseases Ambulatory Clinic. 2005 - present

Small group leader, Pathophysiology Course, Fungal Infection. Second year medical students. April 15, 2009

Lectrer, "Tuberculosis and other Mycobacterial infections". Rhode Island Hospital Internal Medicine Residents noon conference series. August 31, 2009.

Lectrer, "Tuberculosis and other Mycobacterial infections". The Miriam Hospital Internal Medicine Residents noon conference series. September 8, 2009.